MedTrace Logo

Beta Alethine in Treating Patients With Myeloma

NCT00006466 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.

PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm
  • Precancerous Condition

Interventions

DRUG

beta alethine

Sponsors & Collaborators

  • LifeTime Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Suzin Mayerson, PhD · LifeTime Pharmaceuticals

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006466 on ClinicalTrials.gov